EIZO Receives FDA 510(k) Clearance for Breast Tomosynthesis for RadiForce RX850 Multi-Modality Monitor
EIZO has received FDA 510(k) clearance for breast tomosynthesis from the U.S. Food and Drug Administration for its 8 megapixel multi-modality monitor, the RadiForce RX850. Digital breast tomosynthesis is a method of breast screening that allows the radiologist to view detailed 3-dimensional images of the breast assembled from multiple X-ray pictures. When used in combination with digital mammography, tomosynthesis provides radiologists with multiple screening techniques that can be utilized together for increased diagnostic precision in breast cancer detection. With FDA 510(k) clearance for the RadiForce RX850 in tomosynthesis, mammography, and general radiography, EIZO continues to provide a high degree of customer assurance to medical breast screening professionals and their patients.
The RadiForce RX850’s super high-resolution screen (4096 x 2160) displays 8 megapixels of information with a pixel pitch of 0.1704 mm for viewing medical breast images in exceptional detail. To detect the smallest structures, the monitor offers a high contrast ratio of 1450:1. The deeper black levels distinguish similar shades of gray for sharper monochrome image reproduction.